UK markets closed

Can-Fite BioPharma Ltd. (CANF)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
2.0300-0.0600 (-2.87%)
At close: 03:19PM EDT
2.0300 0.00 (0.00%)
After hours: 04:25PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 10.43M
Enterprise value 1.55M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.99
Price/book (mrq)1.67
Enterprise value/revenue 2.08
Enterprise value/EBITDA -0.19

Trading information

Stock price history

Beta (5Y monthly) 0.91
52-week change 3-1.42%
S&P500 52-week change 323.57%
52-week high 33.3300
52-week low 31.8100
50-day moving average 32.1432
200-day moving average 32.2968

Share statistics

Avg vol (3-month) 317.85k
Avg vol (10-day) 313.89k
Shares outstanding 54.99M
Implied shares outstanding 64.08M
Float 81.5B
% held by insiders 10.00%
% held by institutions 14.89%
Shares short (15 Apr 2024) 49.93k
Short ratio (15 Apr 2024) 40.55
Short % of float (15 Apr 2024) 4N/A
Short % of shares outstanding (15 Apr 2024) 40.20%
Shares short (prior month 15 Mar 2024) 410.8k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 310 May 2019
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 309 Jan 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,183.23%

Management effectiveness

Return on assets (ttm)-53.15%
Return on equity (ttm)-142.49%

Income statement

Revenue (ttm)743k
Revenue per share (ttm)0.30
Quarterly revenue growth (yoy)-21.30%
Gross profit (ttm)N/A
EBITDA -8.18M
Net income avi to common (ttm)-7.63M
Diluted EPS (ttm)-3.0000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.92M
Total cash per share (mrq)0.01
Total debt (mrq)40k
Total debt/equity (mrq)0.64%
Current ratio (mrq)4.91
Book value per share (mrq)0.00

Cash flow statement

Operating cash flow (ttm)-8.44M
Levered free cash flow (ttm)-5.12M